ACCEL Lite: Are Primary Prevention ICDs Still Valuable in NICM?

Apr 27, 2021   |  Alison Bailey, MD, FACC; Rachel J. Lampert, MD, FACC; Eric N. Prystowsky, MD, FACC; Michael Robert Gold, MD, PhD, FACC

Podcast

Font Size
A
A
A

Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be considered in patients with NICM and left bundle branch block? What were the data to support the use of ICDs for primary prevention in NICM? In this episode, Rachel Lampert, MD, moderates a debate between Michael R. Gold, MD, PhD, and Eric N. Prystowsky, MD, FACC, about whether primary prevention ICDs are still a valuable therapy in patients with NICM.

Like what you hear? ACCEL Subscribers enjoy 20+ insider interviews like these every month, with CME/MOC credit and other exclusive benefits. Subscribe today for more, and check out what's new at www.acc.org/ACCEL.




Clinical Topics: Arrhythmias and Clinical EP, Heart Failure and Cardiomyopathies, Prevention, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure

Keywords: ACCELLite, Primary Prevention, Cardiomyopathies, Electrophysiology, Cardiac Electrophysiology, Defibrillators, Implantable, Defibrillators, Arrhythmias, Cardiac, Heart Failure


< Back to Listings